Perceptive Advisors Has Lifted Acceleron Pharma (XLRN) Stake By $33.49 Million; Last Week Evercore Inc. (EVR) Analysts

January 14, 2018 - By Vivian Currie

Perceptive Advisors Llc increased Acceleron Pharma Inc (XLRN) stake by 127.24% reported in 2017Q3 SEC filing. Perceptive Advisors Llc acquired 905,000 shares as Acceleron Pharma Inc (XLRN)’s stock declined 4.63%. The Perceptive Advisors Llc holds 1.62 million shares with $60.32 million value, up from 711,259 last quarter. Acceleron Pharma Inc now has $2.04B valuation. The stock increased 2.76% or $1.21 during the last trading session, reaching $45.12. About 666,831 shares traded or 114.63% up from the average. Acceleron Pharma Inc. (NASDAQ:XLRN) has declined 22.43% since January 14, 2017 and is downtrending. It has underperformed by 39.13% the S&P500.

Among 11 analysts covering Evercore Partners (NYSE:EVR), 4 have Buy rating, 0 Sell and 7 Hold. Therefore 36% are positive. Evercore Partners had 27 analyst reports since September 8, 2015 according to SRatingsIntel. The firm earned “Mkt Perform” rating on Monday, March 27 by Keefe Bruyette & Woods. Bank of America upgraded Evercore Inc. (NYSE:EVR) rating on Thursday, February 16. Bank of America has “Buy” rating and $95 target. Instinet downgraded Evercore Inc. (NYSE:EVR) on Monday, February 13 to “Neutral” rating. Goldman Sachs upgraded Evercore Inc. (NYSE:EVR) on Tuesday, January 12 to “Conviction Buy” rating. The stock has “Neutral” rating by UBS on Thursday, February 4. The firm earned “Hold” rating on Friday, May 26 by Keefe Bruyette & Woods. Nomura downgraded the shares of EVR in report on Monday, November 9 to “Neutral” rating. The stock of Evercore Inc. (NYSE:EVR) has “Buy” rating given on Friday, October 28 by Nomura. The firm earned “Positive” rating on Monday, October 12 by Susquehanna. As per Thursday, July 27, the company rating was maintained by Keefe Bruyette & Woods. See Evercore Inc. (NYSE:EVR) latest ratings:

11/01/2018 Broker: Sandler O’Neill Rating: Buy New Target: $104.0 Maintain
10/01/2018 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $97.0 Maintain
09/01/2018 Broker: UBS Rating: Buy New Target: $105.0 Upgrade
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $88.0 Maintain
03/11/2017 Broker: Nomura Rating: Neutral Old Target: $78 New Target: $81 Maintain
27/07/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $87.0000 Maintain

Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. The company has market cap of $4.14 billion. The firm operates through two divisions, Investment Banking and Investment Management. It has a 23.16 P/E ratio. The Investment Banking segment provides advisory services on mergers, acquisitions, divestitures, leveraged buyouts, and similar corporate finance matters; capital markets advice relating to debt and equity securities; and services related to securities underwriting, private placement services, and commissions for agency equity trading services and equity research.

Since August 29, 2017, it had 0 buys, and 1 sale for $1.65 million activity. $1.65M worth of Evercore Inc. (NYSE:EVR) was sold by Walsh Robert B.

The stock increased 2.15% or $2.05 during the last trading session, reaching $97.45. About 427,713 shares traded or 16.18% up from the average. Evercore Inc. (NYSE:EVR) has risen 42.28% since January 14, 2017 and is uptrending. It has outperformed by 25.58% the S&P500.

Investors sentiment decreased to 1.02 in Q3 2017. Its down 0.33, from 1.35 in 2017Q2. It fall, as 28 investors sold Evercore Inc. shares while 98 reduced holdings. 43 funds opened positions while 85 raised stakes. 35.87 million shares or 4.07% less from 37.39 million shares in 2017Q2 were reported. Swiss Bancshares has invested 0.01% in Evercore Inc. (NYSE:EVR). Kennedy Cap Management Inc owns 0.11% invested in Evercore Inc. (NYSE:EVR) for 75,408 shares. Fincl Bank Of America De holds 0.01% or 527,292 shares in its portfolio. Dupont Cap invested in 0.13% or 71,500 shares. Nordea Inv Mngmt Ab holds 26,842 shares or 0.01% of its portfolio. Jennison Assoc Llc accumulated 0% or 20,841 shares. Federated Pa invested in 7,482 shares. Cetera Advsrs Ltd Llc invested in 0.01% or 2,983 shares. Guggenheim Ltd Limited Liability Company accumulated 77,952 shares or 0.01% of the stock. Jpmorgan Chase Co invested 0.01% in Evercore Inc. (NYSE:EVR). Fisher Asset Mgmt Limited Liability owns 65,841 shares or 0.01% of their US portfolio. Boston Private Wealth Ltd Com stated it has 8,920 shares or 0.03% of all its holdings. Oppenheimer Asset Mngmt holds 0.02% in Evercore Inc. (NYSE:EVR) or 9,635 shares. Ameriprise Financial holds 0.02% of its portfolio in Evercore Inc. (NYSE:EVR) for 495,170 shares. Employees Retirement Of Texas owns 39,000 shares for 0.04% of their portfolio.

Perceptive Advisors Llc decreased Dbv Technologies S A stake by 15,346 shares to 576,419 valued at $24.46 million in 2017Q3. It also reduced Viveve Medical Inc stake by 403,480 shares and now owns 486,988 shares. Wave Life Sciences Ltd was reduced too.

Investors sentiment increased to 1.81 in 2017 Q3. Its up 0.37, from 1.44 in 2017Q2. It is positive, as 12 investors sold XLRN shares while 30 reduced holdings. 30 funds opened positions while 46 raised stakes. 37.73 million shares or 12.48% more from 33.54 million shares in 2017Q2 were reported. Evercore Wealth Mgmt Llc holds 32,742 shares or 0.05% of its portfolio. Product Ltd Co has invested 0.08% in Acceleron Pharma Inc. (NASDAQ:XLRN). Envestnet Asset Mngmt reported 0% in Acceleron Pharma Inc. (NASDAQ:XLRN). Oppenheimer And holds 0.01% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 6,031 shares. Loring Wolcott Coolidge Fiduciary Advisors Ltd Liability Partnership Ma owns 337 shares or 0% of their US portfolio. Farallon Capital Mgmt Limited Liability Corp owns 963,000 shares for 0.32% of their portfolio. Ghost Tree Cap Ltd Liability Com has 350,000 shares. Guggenheim Cap Limited Liability Co holds 65,051 shares. Rhumbline Advisers reported 0% stake. Blackrock reported 0.01% stake. Franklin Resource Inc has 462,977 shares. Jane Street Group Inc Inc Limited Liability Company, New York-based fund reported 39,137 shares. Winslow Evans & Crocker Inc holds 0.02% or 1,700 shares in its portfolio. Cormorant Asset Ltd holds 0.49% or 75,000 shares in its portfolio. Qvt Financial LP holds 0.52% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 373,481 shares.

Since August 8, 2017, it had 1 insider buy, and 12 selling transactions for $19.64 million activity. 105,122 shares valued at $3.76M were sold by George Jean on Friday, December 15. 16,000 Acceleron Pharma Inc. (NASDAQ:XLRN) shares with value of $614,546 were sold by MCLAUGHLIN KEVIN F. $197,868 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) was sold by Sherman Matthew L on Wednesday, January 3. Rovaldi Christopher sold 2,266 shares worth $96,134. $182,363 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) shares were sold by Kumar Ravindra. CELGENE CORP /DE/ also bought $27.59 million worth of Acceleron Pharma Inc. (NASDAQ:XLRN) shares. Quisel John D also sold $196,423 worth of Acceleron Pharma Inc. (NASDAQ:XLRN) on Tuesday, September 12.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts